Advertisement
New Zealand markets closed
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NZD/USD

    0.5950
    0.0000 (-0.00%)
     
  • NZD/EUR

    0.5551
    +0.0011 (+0.20%)
     
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • OIL

    84.25
    +0.68 (+0.81%)
     
  • GOLD

    2,360.40
    +17.90 (+0.76%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,128.66
    +49.80 (+0.62%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    18,091.69
    +174.41 (+0.97%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • NZD/JPY

    93.3250
    +0.8290 (+0.90%)
     

Teva’s Key Drugs in Its Specialty Products Pipeline

Teva’s Key Drugs in Its Specialty Products Pipeline

Teva Pharmaceutical’s (TEVA) fremanezumab is a key product awaiting FDA approval. The drug is also under Phase 2 trials for the treatment of post-traumatic headache and a Phase 3 trial for the treatment of cluster headache. The drug is expected to generate significant sales for the company in the years ahead. Teva’s specialty products pipeline is shown in the chart below.